138 results about "Staphylococcus lactis" patented technology

The invention belongs to the technical field of biological medicine, and discloses lactococcus lactis HX21473 and application thereof, the lactococcus lactis HX21473 is preserved in China General Microbiological Culture Collection Center (CGMCC) on January 20, 2025, and the preservation number is CGMCC NO.33476. The invention further discloses a preparation method of the lactococcus lactis HX21473. The invention provides a strain of lactococcus lactis HX21473 capable of efficiently expressing a foreign protein. The lactococcus lactis HX21473 has strong acid resistance, can be used as an oral vaccine live carrier, and promotes research, development and application of oral vaccines.

The invention belongs to the technical field of new energy materials, and particularly relates to a preparation method of a bamboo-based hard carbon sodium ion battery negative electrode material, which specifically comprises the following steps: (1) slicing, crushing, screening, sieving, drying and treating fresh bamboo under steam pressure to obtain bamboo powder; (2) bamboo powder and lactococcus lactis liquid are mixed and fermented, and after fermentation is completed, the bamboo powder and the lactococcus lactis liquid are washed to be neutral and dried; (3) placing the bamboo powder subjected to fermentation treatment in an inert atmosphere, heating, keeping constant temperature, and cooling to obtain a pre-carbonized sample; (4) soaking the pre-carbonized sample in a hydrochloric acid solution, continuously reacting, washing to be neutral, and drying; and (5) continuously heating the acid-washed and dried material in the step (4) in the inert atmosphere, carbonizing at a constant temperature, and cooling to obtain the final sodium-ion battery negative electrode material. The method disclosed by the invention has the advantages of remarkable environmental friendliness, low cost, simplicity and convenience in operation and the like; and the battery negative electrode material prepared by the method disclosed by the invention has excellent electrochemical performance.

The invention belongs to the field of microorganisms, and particularly relates to lactococcus lactis Jlus 880314 and application thereof. The strain is classified and named as Lactococcus lactis, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing; the preservation number of the strain is CGMCC No. 33961. Time-of-flight mass spectrometry analysis shows that nisin exists in a metabolite of the strain, and the strain can be used for producing nisin. The compound shows an excellent and wide antibacterial function in antibacterial experiments, can be used for preparing antibacterial drugs, particularly has a remarkable inhibiting effect on growth of gram-negative bacteria and fungi, can be used for preparing drugs for relieving or treating enteritis, or preparing drugs, nourishment or health care products for regulating gastrointestinal tract micro-ecological balance of people or animals, and can be used for preparing medicines for relieving or treating enteritis. The compound can also be used for preparing antibacterial food additives and / or animal feed additives. A hemolysis experiment result shows that hemolysis is avoided, toxic and side effects are small, and wide development prospects and application values are achieved.

The invention relates to a polygonatum sibiricum probiotic compound preparation with an aging delaying effect and application thereof. The compound preparation comprises a polygonatum sibiricum extract and a probiotic composition, the bacterial strains in the probiotic composition comprise a combination of a bifidobacterium animalis subsp. Lactis BLa36 bacterial strain, a bifidobacterium longum BL21 bacterial strain, a bifidobacterium adolescentis BAC30 bacterial strain, a lactobacillus plantarum Lp90 bacterial strain, a lactobacillus casei LC89 bacterial strain, a bifidobacterium breve BBr60 bacterial strain and a pediococcus acidilactici CCFM7902 bacterial strain. After the rhizoma polygonati component and the probiotic component are combined for use, the rhizoma polygonati component and the probiotic component have potential synergistic effects in the aspects of improving the intestinal flora structure, regulating the intestinal environment, delaying senescence, reducing inflammation-related symptoms and the like. Moreover, further, various probiotic strains are compounded and combined for use, so that the capability of a related compound preparation in the aspect of delaying various symptoms of senescence can also be improved in a combined manner.

The invention belongs to the technical field of biomedical treatment and biological fermentation, discloses a metagen composition for effectively inhibiting oral dental caries and application thereof, and aims to solve the problems of great side effect, weak effect and unknown mechanism of the existing dental caries prevention and treatment means. The composition is prepared by mixing a metagen 1 which is prepared by fermenting lactobacillus salivarius Postbio-YY with a metagen 2 which is prepared by fermenting lactococcus lactis Postbio-F3 and lactobacillus paracasei Postbio-P6 step by step. In the preparation process, the active ingredients are reserved by accurately controlling the fermentation pH, time and pasteurization parameters. The composition can be prepared into multiple dosage forms such as toothpaste and the like, can remarkably inhibit the growth of streptococcus mutans and destroy the thallus structure, inhibits biofilm and exopolysaccharide synthesis by down-regulating fimI, wcaJ and wcae genes, is safe and free of side effects, and provides an efficient scheme for decayed tooth prevention and treatment.

The invention relates to the technical field of functional microbial preparations, in particular to a biological preparation for relieving intestinal discomfort caused by alcohol and a preparation method and application thereof.The main technical scheme is that the biological preparation is prepared from, by weight, 5-20 parts of bacillus coagulans, 10-30 parts of pediococcus pentosaceus, 5-10 parts of lactobacillus rhamnosus and 0-20 parts of saccharomycetes. 0-5 parts of bifidobacterium longum and 0-5 parts of lactococcus lactis. By constructing an alcohol metabolism-intestinal protection dual-function synergistic system, specific florae such as bacillus coagulans, pediococcus pentosaceus and lactobacillus rhamnosus are scientifically compatible with functional components such as inulin and L-cysteine, alcohol is efficiently metabolized, and a carbon source is generated; the technical problems of low metabolic efficiency, weak intestinal protection and serious gastric acid inactivation of a traditional product are comprehensively solved.

The invention relates to selenium-enriched pediococcus acidilactici Se34 with anti-oxidation, cholesterol-lowering and anti-tumor effects and application of the selenium-enriched pediococcus acidilactici Se34. The pediococcus acidilactici Se34 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number of the pediococcus acidilactici Se34 is CGMCC No.33933, and the preservation date of the pediococcus acidilactici Se34 is March 24, 2025. The pediococcus acidilactici Se34 provided by the invention integrates excellent probiotic characteristics (acid-resistant bile salt, safe and colonizable), efficient selenium enrichment capacity and remarkably enhanced activity of resisting oxidation, reducing cholesterol and inhibiting specific cancer cell proliferation and metastasis after selenium enrichment. The strain and the selenium-rich product thereof have important application value in the fields of developing functional foods (selenium-rich probiotic products), antioxidant / cholesterol-reducing health-care foods, potential auxiliary anticancer biological preparations or prodrugs and the like.

The application discloses a Vibrio harveyi oral vaccine and a preparation method and application thereof. The application uses a lactococcus lactis NZ9000 expression system, modifies transformation parameters, effectively expresses Vibrio harveyi OmpU protein, constructs a lactococcus lactis (NZ9000) engineering bacterium expressing Vibrio harveyi outer membrane protein (OmpU), develops an oral vaccine against Vibrio harveyi infection, aims to reduce the infection of economic animals in seawater aquaculture by oral administration, provides a new scheme for dealing with the harm of Vibrio harveyi infection and antibiotic resistance and the like, promotes the breeding of fry and fingerlings, and promotes the development of biological agriculture and related industries. The strategy is expected to overcome the problems of traditional injection vaccines, such as inconvenient operation and great stress, and can provide a new technical scheme for reducing the dependence of the aquaculture industry on antibiotics and promoting the establishment of a green and healthy breeding mode.

The invention discloses a method for improving yield of branched chain aldehyde of lactococcus lactis based on regulation and control of a luxS gene and application, and belongs to the field of system biology. Gene function verification and genome scale metabolic network model analysis are creatively combined, the phenotypic effect of the luxS gene is confirmed, and more importantly, the internal action mechanism of the luxS gene is disclosed from the system level, that is, the whole metabolic network flow is influenced by regulating and controlling multiple key enzymes such as transaminase, decarboxylase, dehydrogenase and decarboxylase. The invention reveals that the quorum sensing core gene luxS has a new function of regulating and controlling synthesis of branched chain aldehyde in lactococcus lactis for the first time, and an intercellular communication system is directly linked with production of specific flavor metabolites. The invention provides a brand-new and higher-level regulation target and thought for producing flavor substances by microbial fermentation, and gets rid of the limitation that only metabolic pathway terminal enzyme is singly modified traditionally.

The application discloses a beta-1,4-xylanase mutant and a construction method thereof, and comprises the following steps: constructing a beta-1,4-xylanase recombinant expression vector; introducing the recombinant vector pNZ8048-P5-XynA into a competent lactococcus lactis by using an electrotransformation technology to construct a wild-type expression vector; on the basis, designing and constructing a multi-site mutant recombinant plasmid by using a site-directed mutation method, wherein the eighth asparagine (Asn) of the beta-1,4-xylanase is mutated into tyrosine (Tyr), the 22nd serine (Ser) is mutated into proline (Pro), and the 59th alanine (Ala) is mutated into lysine (Lys); introducing the multi-site mutant recombinant plasmid into the competent lactococcus lactis to construct a heterologous expression strain of the mutant beta-1,4-xylanase (Mut-1); and stably obtaining the mutant xylanase beta-1,4-xylanase (Mut-1) with high activity by using a metal affinity chromatography (Ni 2+ ) method. The specific enzyme activity of the mutant reaches 1929.30±5.36 U / mg, and the optimal temperature is increased by 15 DEG C compared with that of the wild type.

A starter culture for the fermentation of a plant-based milk alternative is provided, which is particularly suitable for the production of a plant-based yogurt alternative. The starter culture comprises lactic acid bacteria isolated from legume plant material, especially pea plant material. Preferably, the starter culture comprises lactic acid bacteria of the species Lactobacillus rhamnosus and / or Lactococcus lactis subsp. cremoris.

The application provides a lactococcus lactis, a compound dairy product fermenting agent and application thereof, the lactococcus lactis has the functions of sweetening and flavoring, and is classified and named as lactococcus lactis Lactococcus lactis The strain has significant sweetening and flavoring characteristics, exhibits strong fructo-oligosaccharide (FOS) and acetaldehyde generation capacity in the fermentation process, can provide endogenous sweet taste and aroma flavor substances for fermented milk, and significantly improves the taste and flavor of the fermented milk.The lactococcus lactis C15 is compounded with lactobacillus casei AU9077 and lactobacillus rhamnosus AU9260 to obtain a compound dairy product fermenting agent, which has a significant synergistic effect in releasing fructo-oligosaccharide, continuously provides stable endogenous sweetening effect for fermented milk, improves the quality of dairy products, and meets the needs of consumers for healthy and flavored dairy products.

This invention aims to address the technical bottlenecks of existing milk curd products, such as weak functional activity, unclear process parameters, and unstable flavor and quality. It utilizes *Pediococcus pentosaceus* HM4, *Streptococcus thermophilus* HM6, *Lactococcus lactis* JY4, and *Lactobacillus plantarum* NC1, employing these four strains in an optimal ratio as a compound fermentation agent to achieve synergistic effects. Using milk and goji berries as raw materials, the fermentation process of milk curds and goji berry milk curds was systematically optimized through single-factor experiments, Plackett-Burman experiments, and response surface methodology. The physicochemical indicators and flavor characteristics of the products under different process conditions were analyzed. The obtained milk curds achieved a DPPH free radical scavenging rate of 91.38%–94.15%, providing technical support for the high-value utilization of milk curds and enriching the variety of functional dairy products.

A composition for use in treating or preventing colorectal cancer (CRC) comprising or a fraction of Lactococcus lactis supernatant having a molecular weight greater than 100 kDa which may be obtained by filtration through a 100 kDa molecular weight filter. The composition also comprises a physiologically acceptable excipient and the fraction may be a protein fraction of the L. lactis supernatant. The composition may be formulated for oral ingestion, a powder, liquid, paste, cream, tablet, capsule, or caplet or in a food or beverage item. Additionally, the composition may be formulated in a daily dosage. Also claimed is a kit for treating or preventing colorectal cancer wherein a first container comprises the fraction of L. lactis culture supernatant.

The invention belongs to the technical field of gene engineering, and particularly relates to an efficient electrotransformation method of lactococcus lactis BL19. According to the method disclosed by the invention, the electric shock conversion efficiency of the lactococcus lactis BL19 is remarkably improved, and a foundation is laid for genetic engineering transformation in the future.

The invention belongs to the technical field of biology, and particularly relates to a recombinant strain of high-yield riemerella anatipestifer bacteriophage lyase, a mutant strain, a construction method and application. The invention provides a coding gene of riemerella anatipestifer bacteriophage lyase, and further constructs recombinant lactococcus lactis of high-yield riemerella anatipestifer bacteriophage lyase. The mutant strain provided by the invention is obtained by taking the recombinant lactococcus lactis as a starting strain through a mutation breeding technology and a specific high-throughput screening strategy, has higher secretory expression quantity of riemerella anatipestifer bacteriophage lyase, is good in hereditary stability in an antibiotic-free culture medium, and has a good application prospect. The method is suitable for industrial efficient production of active lyase. The riemerella anatipestifer bacteriophage lyase expressed by the mutant strain has an obvious splitting effect on riemerella anatipestifer in vitro, has obvious prevention and treatment effects on riemerella anatipestifer infection in vivo, and can effectively improve the survival rate of infected chicks and remove pathogenic bacteria in vivo.

The application discloses a kind of complex fermentation inoculant for improving equol production, fermentation liquor and application thereof, belong to microbial fermentation technical field.The complex fermentation inoculant of the application, streptococcus thermophilus BLCC2-0025 and lactococcus lactis MP1001 have high β-glucosidase activity, and low activity glycoside form is converted into high activity daidzein;Salivary lactobacillus LS1101 and lactobacillus gregius 0010 have the activity of further converting daidzein into equol;Four strains of bacteria are used in combination, which can synergistically improve the content of equol.The fermentation liquor prepared by fermenting pueraria extract with the complex fermentation inoculant of the application can target regulate intestine-ovary axis, significantly improve the reproductive function of POF mice, relieve ovarian oxidative stress and accurately regulate intestinal flora balance, providing a safe and effective preparation and application scheme for non-hormone intervention of premature ovarian failure.

This invention discloses a *Lactococcus faecium* strain, YS-IM01. This strain can efficiently hydrolyze sheep colostrum proteins and specifically release a large amount of leucine. This invention also provides a polypeptide composition comprising multiple active peptides with potential for muscle synthesis, immunomodulation, and antioxidant activity. This invention further provides a fermented sheep colostrum product obtained by fermenting sheep colostrum with the aforementioned *Lactococcus faecium*. This invention also provides a method for preparing the fermented sheep colostrum product, comprising steps including fermentation, low-temperature vacuum concentration, and vacuum freeze-drying. Simultaneously, this invention also provides a method for preparing a drug using *Lactococcus faecium* and the polypeptide composition to prevent and / or improve age-related muscle loss.

The present invention relates to the strain Lactococcus lactis subsp. lactis CECT 31096, to its cellular components, metabolites, and secreted molecules, and to compositions comprising the above products, as well as to their uses as a medicament, preferably for the prevention and / or reduction of hypertension, or as a food composition or nutraceutical.

The present invention relates to a composition for treating, ameliorating and preventing liver diseases, comprising a Lactococcus lactis strain, amino acids, and a vitamin. Specifically, the present invention relates to a composition for treating, ameliorating and preventing fatty liver, comprising Lactococcus lactis KF140, tryptophan, histidine, and vitamin E.

The application relates to the field of food biotechnology, and discloses a low-salt bean paste production process based on segmented temperature control fermentation, which is made of fava bean koji, water, edible salt, sodium hexametaphosphate, lactococcus lactis nisin, edible alcohol, granulated coarse granular calcium carbonate and glucono-delta-lactone. The production process comprises the following steps: constructing a composite matrix, and first performing buffer-type medium-temperature enzymolysis; then adding a glucono-delta-lactone aqueous solution in a flow manner, utilizing the stoichiometric coupling reaction of the glucono-delta-lactone aqueous solution and the granulated coarse granular calcium carbonate to generate carbon dioxide in situ to construct a micropore structure and regulate the pH value of the system; and finally, connecting a Zygosaccharomyces rouxii to perform low-temperature aroma-producing after-ripening. Through the synergistic effect of the components, the application effectively solves technical problems in the low-salt fermentation process, such as low protein solubility, easy compaction of the matrix and breeding of miscellaneous bacteria, and improves the amino acid nitrogen content and protein hydrolysis rate of the finished product.

A composition for use in treating or preventing colorectal cancer (CRC) comprising indole-3-Iactic acid (ILA) or an aminopeptidase produced by Lactococcus lactis, the aminopeptidase having a molecular

The application discloses a lactococcus lactis GL-1 and application of the lactococcus lactis GL-1 in Apostichopus japonicus breeding, and belongs to the field of aquatic beneficial microorganisms and application technologies thereof. The lactococcus lactis GL-1 is preserved in the China General Microbiological Culture Collection Center on September 16, 2025, and the preservation number is CGMCC No. 35938, and the lactococcus lactis GL-1 is isolated from traditional fermented food doubansauce. The strain can well adapt to different environments, and can be used for preparing an Apostichopus japonicus feed additive. When the number of viable lactococcus lactis GL-1 in the feed is greater than or equal to 1x10 8 CFU / g, the low-salt stress resistance of the Apostichopus japonicus can be significantly enhanced, the survival rate and growth performance are improved, the intestinal flora structure is improved, the colonization of beneficial bacteria is promoted, and immune-related pathways such as the Wnt signal pathway are activated, so that the health level of the Apostichopus japonicus is improved from multiple aspects. A safe and effective microbial solution is provided for solving the low-salt stress problem in the Apostichopus japonicus breeding.

The application discloses a Leuconostoc intestini and Lactococcus lactis composition and application, belongs to the field of microbial pharmacy, and relates to application of a Leuconostoc intestini and Lactococcus lactis composition to preparation of a drug for treating pulmonary fibrosis diseases; wherein the quantity of the Leuconostoc intestini and the Lactococcus lactis in the composition is equal in terms of colony forming units. Experimental results show that the Leuconostoc intestini and the Lactococcus lactis can effectively improve pulmonary fibrosis when being intervened alone or in combination. It is known to those skilled in the art that excessive deposition of collagen fibers is a core feature of pulmonary fibrosis diseases, and the Leuconostoc intestini and the Lactococcus lactis have a synergistic effect of inhibiting the content of lung tissue collagen in pulmonary fibrosis. Therefore, the Leuconostoc intestini and the Lactococcus lactis composition has a prospect of being developed into a drug for treating pulmonary fibrosis diseases (including idiopathic pulmonary fibrosis and secondary pulmonary fibrosis).

The application belongs to the technical field of biological gene engineering, and discloses a lactococcus lactis carrier oral vaccine for producing enterotoxigenic escherichia coli F18 pilus type and application. Four lactococcus lactis antigen surface display strains are prepared, and are mixed to perform oral immunization. The oral immunization mode is convenient to operate, avoids the stress reaction caused by injection immunization on animals, and greatly improves the immunization effect, so that the diarrhea caused by enterotoxigenic escherichia coli on piglets can be effectively prevented. 50 The application is an oral escherichia coli vaccine, and mouse immunization challenge experiment shows that all the mice can survive under the challenge dose of LD , and piglet immunization challenge experiment shows that the piglets can be 100% protected from diarrhea, which shows that the immunization group has effective mucosal immune protection ability.

This invention provides a set-type yogurt with a milk skin layer and its production method, relating to the field of dairy product technology. The invention involves mixing raw milk with white sugar and a stabilizer, cooling it, and then adding functional excipients to obtain base material 1. The raw milk is then centrifuged and defatted to prepare light cream, yielding base material 2. Base material 1 and base material 2 are mixed, inoculated with a complex microorganism, and subjected to static fermentation followed by low-temperature ripening. The stabilizer consists of acetylated distarch adipate, κ-carrageenan, and diacetyl tartaric acid mono- and diglycerides. The complex microorganisms consist of *Streptococcus thermophilus* subsp. *salicylate*, *Lactococcus lactis* subsp. *lactophores*, and *Bifidobacterium animalis* subsp. *lactophores*. The stabilizer enhances gel water retention and reduces whey separation, allowing the light cream to float and form a uniform and dense milk skin layer. The static fermentation and low-temperature ripening of the complex microorganisms optimize texture and flavor. The milk skin layer of this invention's set-type yogurt is intact and uniform in thickness, the yogurt curd is delicate, whey separation is minimal, and the taste is rich and mellow.

The invention relates to a sensitive skin micro-ecological balance-oil control and acne removal composition and application thereof. The composition is prepared from the following components: lactococcus lactis / phellinus pharmacologically fermented product filtrate, lactobacillus / black mustard seed fermented product extract, citrus fruit extract and trifolium pretense flower extract. The weight ratio of the lactococcus lactis / phellinus pharmacologically fermented product filtrate to the lactobacillus / black mustard seed fermented product extract to the citrus fruit extract to the trifolium pretense flower extract is (0.1-8): (0.001-0.1): (0.001-0.2): (0.01-3), and the composition constructs a four-stage synergistic mechanism of flora regulation, barrier repair, oil control and fat suppression, anti-inflammation and soothing; the limitation of a single target spot in the traditional technology is broken through, and an efficient, safe and multi-dimensional regulation and control comprehensive solution is provided for oily sensitive skin micro-ecological balance.

The application relates to application of lactococcus lactis in a composition for inhibiting streptococcus pyogenes and angina streptococcus and a product, and belongs to the field of microbial technology. The technical problem to be solved is to provide application of lactococcus lactis in preparation of a composition for inhibiting streptococcus pyogenes and angina streptococcus or treating tumors, and the technical solution points are that the lactococcus lactis is applied in preparation of the composition for inhibiting streptococcus pyogenes and angina streptococcus. The lactococcus lactis OA56 of the application can efficiently inhibit streptococcus pyogenes and angina streptococcus, has low ability of forming a biological membrane, shows strong adhesion to oral epithelial cells and hydroxyapatite, can effectively relieve clinical symptoms caused by streptococcus pyogenes infection, reduce inflammation reaction of gastric epithelial cells induced by angina streptococcus infection, and can treat or assist in treating angina streptococcus related tumors.

The invention relates to the technical field of minced fillet deodorization, and discloses a minced fillet deodorization process for fish ball production, which comprises the following steps: (1) cleaning and dehydrating a minced fillet raw material, and controlling the water content at 80-95% after the raw material is dehydrated to obtain a primary minced fillet raw material; (2) activating a composite fungus material, adding the activated composite fungus material into the primary minced fillet raw material, uniformly stirring, fermenting at 28 DEG C for 50-60 minutes, heating to 30 DEG C, and fermenting for 50-60 minutes; wherein the composite fungus material comprises rhizomucor miehei, kluyveromyces marxianus, lactococcus lactis and saccharomyces cerevisiae; and (4) heating the minced fillet obtained in the step (3) to 65-68 DEG C, keeping the temperature for 2-3 minutes, rinsing with ice water, and dehydrating to obtain the fishy smell removed minced fillet. According to the method, the effect of removing the fishy smell of the minced fillet can be improved.